Zimmer Biomet Holdings (ZBH) Tops Q3 EPS by 74c, Revenues Beat

Zimmer Biomet Holdings (NYSE: ZBH) reported Q3 EPS of $1.81, $0.74 better than the analyst estimate of $1.07. Revenue for the quarter came in at $1.93 billion versus the consensus estimate of $1.71 billion.

• Third quarter net sales of $1.929 billion increased 2.0%, and increased 1.1% on a constant currency basis
• Third quarter diluted earnings per share were $1.16; adjusted diluted earnings per share were $1.81

"While the stronger than expected recovery of elective procedures in the third quarter was encouraging, we also remain focused on ZB's strong operational execution, which continues to drive confidence in our underlying business," said Bryan Hanson, President and CEO of Zimmer Biomet. "It is important to note that the challenges and fluidity around COVID-19 persist as we move into the end of the year. Still, we will continue to transform our business, invest for greater value and prioritize innovation to better position the Company for accelerated growth over the long term. I am so proud of our global team for the support we provide healthcare professionals and patients every day and our ongoing commitment to the ZB mission to better the lives of people around the world."

For earnings history and earnings-related data on Zimmer Biomet Holdings (ZBH) click here.

You May Also Be Interested In

• Zimmer Biomet to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
• Delta Air Lines: demand remains strong despite global uncertainty
• Oil-Dri raises dividend for 23rd consecutive year, authorizes buybacks